Voyager wins FDA IND clearance for Alzheimer’s gene therapy VY1706
VYGR•FDA clears Voyager’s IND for VY1706
Voyager Therapeutics received FDA IND clearance for VY1706, enabling a clinical trial in adults with early Alzheimer’s disease.
- Dosing is expected to begin in H2 2026.*
